Stockscreener 앱 받기
21.53
1.01%
-0.22
시장 영업 전:
21.40
-0.13
-0.60%
전일 마감가:
$21.75
열려 있는:
$21.72
하루 거래량:
2.01M
Relative Volume:
0.38
시가총액:
$2.26B
수익:
$2.48B
순이익/손실:
$-57.96M
주가수익비율:
-28.38
EPS:
-0.7585
순현금흐름:
$-453.97M
1주 성능:
-3.28%
1개월 성능:
+19.61%
6개월 성능:
-42.29%
1년 성능:
-82.70%
1일 변동 폭
$21.18
$21.74
1주일 범위
$20.76
$22.85
52주 변동 폭
$10.41
$129.84
사렙타 테라퓨틱스 Stock (SRPT) Company Profile
명칭
Sarepta Therapeutics Inc
전화
617-274-4000
주소
215 FIRST STREET, CAMBRIDGE, MA
SRPT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
21.53 | 2.28B | 2.48B | -57.96M | -453.97M | -0.7585 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
사렙타 테라퓨틱스 Stock (SRPT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Wedbush | Outperform |
| 2025-11-05 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2025-09-22 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-29 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2025-07-29 | 개시 | Bernstein | Mkt Perform |
| 2025-07-29 | 재확인 | H.C. Wainwright | Sell |
| 2025-07-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2025-07-29 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-07-28 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2025-07-25 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-07-24 | 개시 | Citigroup | Sell |
| 2025-07-23 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2025-07-22 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-07-21 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2025-07-21 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-07-21 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2025-07-21 | 다운그레이드 | Needham | Hold → Underperform |
| 2025-07-21 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-07-18 | 다운그레이드 | Needham | Buy → Hold |
| 2025-06-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-06-18 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-06-17 | 개시 | Wolfe Research | Peer Perform |
| 2025-06-16 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2025-06-16 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-06-16 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-06-16 | 다운그레이드 | H.C. Wainwright | Neutral → Sell |
| 2025-06-16 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-06-16 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-06-06 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
| 2025-05-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-04-11 | 개시 | Wells Fargo | Overweight |
| 2025-04-02 | 업그레이드 | H.C. Wainwright | Sell → Neutral |
| 2025-03-31 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2024-11-27 | 재확인 | Needham | Buy |
| 2024-11-25 | 개시 | H.C. Wainwright | Sell |
| 2024-11-07 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | 개시 | Jefferies | Buy |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-07-29 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-05-28 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-01-31 | 개시 | BMO Capital Markets | Outperform |
| 2023-12-13 | 재개 | Citigroup | Buy |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-11-21 | 개시 | Wedbush | Outperform |
| 2023-10-31 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-06-23 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-04-26 | 개시 | SMBC Nikko | Outperform |
| 2023-04-04 | 개시 | Citigroup | Buy |
| 2023-03-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | 재확인 | BTIG Research | Buy |
| 2022-12-16 | 업그레이드 | UBS | Neutral → Buy |
| 2022-04-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-01-05 | 재확인 | Needham | Buy |
| 2021-12-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-11-05 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-09-15 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-08-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-01-12 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-01-11 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-01-08 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2021-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | 개시 | Berenberg | Hold |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-08-20 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | 개시 | Mizuho | Buy |
| 2019-11-01 | 개시 | Guggenheim | Buy |
| 2019-08-21 | 재확인 | Needham | Buy |
| 2019-07-09 | 재확인 | Morgan Stanley | Overweight |
| 2019-07-01 | 재확인 | RBC Capital Mkts | Outperform |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-11 | 재확인 | Credit Suisse | Outperform |
| 2018-10-12 | 개시 | Bernstein | Outperform |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-26 | 재확인 | RBC Capital Mkts | Outperform |
| 2018-09-14 | 재개 | BofA/Merrill | Buy |
| 2018-09-06 | 개시 | Credit Suisse | Outperform |
| 2018-08-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | 재확인 | Robert W. Baird | Outperform |
| 2018-06-20 | 재확인 | Needham | Buy |
| 2018-06-19 | 재확인 | H.C. Wainwright | Buy |
모두보기
사렙타 테라퓨틱스 주식(SRPT)의 최신 뉴스
A mom was overjoyed when she learned a drug could save her baby's life. Then she learned it cost $2 million. - CBS News
683 Capital Management LLC Grows Stock Position in Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap DownHere's What Happened - MarketBeat
Sarepta Therapeutics Refinances Convertible Senior Notes - The Globe and Mail
Sarepta CEO given first equity award in 8 years - The Business Journals
Arrowhead Pharma secures $200M milestone from Sarepta Therapeutics - MSN
Mizuho reiterates Outperform rating on Sarepta stock amid debt refinancing - Investing.com
Mizuho reiterates Outperform rating on Sarepta stock amid debt refinancing By Investing.com - Investing.com UK
Sarepta Therapeutics stock falls after debt exchange announcement By Investing.com - Investing.com South Africa
Sarepta Therapeutics stock falls after debt exchange announcement - Investing.com
Why Is SRPT Stock Falling Today? - Stocktwits
Sector Update: Health Care Stocks Mixed Premarket Thursday - marketscreener.com
Sarepta dips after announcing debt refinancing - TradingView
Sarepta Therapeutics stock falls after refinancing of convertible notes By Investing.com - Investing.com South Africa
Sarepta to refinance $291M of existing notes due 2027 - MSN
Sarepta Therapeutics Refinances $291 Million in Convertible Senior Notes Due 2027 - marketscreener.com
Sarepta Therapeutics announces refinancing of approximately $291 million of 1.25% convertible senior notes due 2027 - marketscreener.com
Sarepta to exchange $291.4 million in convertible notes - Investing.com
Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027 - Business Wire
Sarepta Therapeutics' Myotonic Dystrophy Type 1 Trial Data Could Boost Investor Sentiment, Oppenheimer Says - marketscreener.com
United States Gene Therapy Market to Hit $6510.45 Million by 2033 - openPR.com
Sarepta Therapeutics, Inc. $SRPT Shares Bought by Federated Hermes Inc. - MarketBeat
Sarepta Therapeutics (NASDAQ:SRPT) Nasdaq Index Tracks Biotech Advancements - Kalkine Media
Sarepta Therapeutics (SRPT): Reassessing Valuation After a Sharp One-Month Share Price Rebound - Yahoo Finance
Is Sarepta Therapeutics a Bargain After Recent Share Rebound and DCF Valuation Check? - Yahoo Finance
Sarepta Therapeutics Gets A Vote Of Confidence After Sell-Off - Finimize
Wedbush Says Sarepta Selloff “Overdone” - GuruFocus
Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap UpWhat's Next? - MarketBeat
Sarepta Offers 'Attractive' Entry Point After Setbacks, Wedbush Says - marketscreener.com
Sarepta Therapeutics (SRPT) Rated Outperform by Wedbush with 46% Upside Potential - GuruFocus
Sarepta a new outperform at Wedbush as selloff overdone - Seeking Alpha
Sarepta Therapeutics (NASDAQ:SRPT) Coverage Initiated by Analysts at Wedbush - MarketBeat
SRPT: Wedbush Initiates Coverage with Outperform Rating | SRPT S - GuruFocus
Wedbush initiates Sarepta Therapeutics stock coverage with Outperform rating - Investing.com
Wedbush initiates Sarepta Therapeutics stock coverage with Outperform rating By Investing.com - Investing.com UK
Sarepta (SRPT) Stock Outlook: Wedbush Predicts Potential Growth - GuruFocus
Regenerative Medicine Market 2025-2033: Key Trends, Research - openPR.com
New York State Common Retirement Fund Sells 7,923,000 Shares of Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Norges Bank Buys Shares of 913,407 Sarepta Therapeutics, Inc. $SRPT - MarketBeat
Sarepta Therapeutics (SRPT) Is Up 6.8% After FDA Clears Cohort 8 Dosing in ENDEAVOR Trial - simplywall.st
Dyne Readies DMD Exon-Skipper For Filing, Could Be Competitive With Sarepta Drug - Citeline News & Insights
Sarepta Therapeutics grants $12 million equity award to CEO Douglas Ingram - Investing.com Nigeria
Why Is Dyne Therapeutics Stock Surging Monday?Dyne Therapeutics (NASDAQ:DYN), Sarepta Therapeutics (NASDAQ:SRPT) - Benzinga
Dyne readies FDA push after DMD exon 51 med excels in trial - Fierce Biotech
Sarepta Therapeutics grants $12 million equity award to CEO Douglas Ingram By Investing.com - Investing.com South Africa
Sarepta Grants CEO Equity Awards After Eight Years - TipRanks
Dyne Therapeutics plans to file for approval for next-generation Duchenne drug - statnews.com
Sarepta Therapeutics Inc Stock Baskets - GuruFocus
Sarepta Therapeutics Inc Stock Operating Data - GuruFocus
Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Shares Bounce 26% But Its Business Still Trails The Industry - 富途牛牛
Sarepta Therapeutics (SRPT): Valuation Check After New ENDEAVOR Dosing Approval and SRP-1003 Pipeline Milestones - simplywall.st
사렙타 테라퓨틱스 (SRPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.08%
0.91%
자본화:
|
볼륨(24시간):